Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): 
April 28, 2022
Johnson & Johnson
 (Exact name of registrant as specified in its charter)
New Jersey 1-3215 22-1024240
(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

One Johnson & Johnson Plaza, New Brunswick, New Jersey  08933 
(Address of Principal Executive Offices)
 (Zip Code) 
Registrant's telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 
            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
               CFR 240.14d-2(b)) 
            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
               CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, Par Value $1.00 JNJ New York Stock Exchange
0.650% Notes Due May 2024 JNJ24C New York Stock Exchange
5.50% Notes Due November 2024 JNJ24BP New York Stock Exchange
1.150% Notes Due November 2028 JNJ28 New York Stock Exchange
1.650% Notes Due May 2035 JNJ35 New York Stock Exchange
  Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company    

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

The information included in the third bullet under Item 5.07(b) below is incorporated herein by reference.

Item 5.07 Submission of Matters to a Vote of Security Holders.

(a)    The 2022 Annual Meeting of Shareholders was held on April 28, 2022.

(b)    At the 2022 Annual Meeting of Shareholders, the shareholders:

elected all 14 Director nominees named in the 2022 Proxy Statement to the Company's Board of Directors;

approved, on an advisory basis, the executive compensation philosophy, policies and procedures described in the “Compensation Discussion and Analysis” section of the 2022 Proxy Statement and the compensation of the Company's executive officers named in the 2022 Proxy Statement, as disclosed therein;

approved the Company's 2022 Long-Term Incentive Plan (the ”2022 Plan”), which was previously approved by the Company's Board of Directors on March 7, 2022; a description of the terms and conditions of the 2022 Plan and the amounts payable thereunder is included in the 2022 Proxy Statement under "Item 3: Approval of the Company's 2022 Long-Term Incentive Plan,” beginning on page 110 of the 2022 Proxy Statement; the description of the 2022 Plan in the 2022 Proxy Statement is qualified in its entirety by reference to the full text of the 2022 Plan, which is attached as Appendix A to the 2022 Proxy Statement;

ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year 2022;

did not approve the shareholder proposal for a civil rights, equity, diversity & inclusion audit proposal;

approved the shareholder proposal for a third party racial justice audit;

did not approve the shareholder proposal for a report on government financial support and access to COVID-19 vaccines and therapeutics;

did not approve the shareholder proposal for a report on public health costs of protecting vaccine technology;

did not approve the shareholder proposal to discontinue global sales of baby powder containing talc;

did not approve the shareholder proposal for a request for charitable donations disclosure;

did not approve the shareholder proposal for a third party review and report on lobbying activities alignment with the Company's position on universal health coverage;

did not approve the shareholder proposal to adopt policy to include legal and compliance costs in incentive compensation metrics; and

did not approve the shareholder proposal for CEO compensation to weigh workforce pay and ownership.

The following are the final voting results for each of the thirteen items voted on at the meeting.

1.    Election of Directors:
Shares For Shares Against Shares Abstain Non-Votes
D. Adamczyk 1,821,875,407  21,631,193  5,530,991  346,482,920
M. C. Beckerle 1,827,119,327  16,556,459  5,361,805  346,482,920
D. S. Davis 1,804,888,350  38,606,493  5,542,748  346,482,920
I. E. L. Davis 1,794,374,557  48,881,358  5,781,676  346,482,920
J. A. Doudna 1,821,404,683  22,800,923  4,831,985  346,482,920
J. Duato 1,835,249,999  8,652,237  5,135,355  346,482,920
A. Gorsky 1,744,897,480  98,478,059  5,662,052  346,482,920
M. A. Hewson 1,792,683,677  51,493,950  4,859,964  346,482,920
H. Joly 1,793,561,898  49,872,480  5,603,213  346,482,920
M. B. McClellan 1,695,564,934  147,919,856  5,552,801  346,482,920
A. M. Mulcahy 1,730,711,988  113,274,497  5,051,106  346,482,920
A. E. Washington 1,802,878,123  40,670,398  5,489,070  346,482,920
M. A. Weinberger 1,815,423,637  28,240,835  5,373,119  346,482,920
N. Y. West 1,834,814,211  8,991,427  5,231,953  346,482,920

2.    Advisory Vote to Approve Named Executive Officer Compensation:
For 1,579,815,895 
Against 257,738,128 
Abstain 11,483,568 
Non-Votes 346,482,920 

3.    Approval of the Company's 2022 Long-Term Incentive Plan
For 1,675,020,466 
Against 165,231,757 
Abstain 8,785,368 
Non-Votes 346,482,920 

4.    Ratification of Appointment of PricewaterhouseCoopers LLC as the Independent Registered Public Accounting Firm for 2022:
For 2,041,408,099 
Against 147,081,482 
Abstain 7,030,930 
Non-Votes N/A

6.    Shareholder Proposal - Civil Rights, Equity, Diversity & Inclusion Audit Proposal:
For 50,182,969 
Against 1,777,981,079 
Abstain 20,873,543 
Non-Votes 346,482,920 

7.    Shareholder Proposal - Third Party Racial Justice Audit:
For 1,144,529,241 
Against 682,570,135 
Abstain 21,938,215 
Non-Votes 346,482,920 

8.    Shareholder Proposal - Report on Government Financial Support and Access to COVID-19 Vaccines and Therapeutics:
For 616,715,019 
Against 1,207,732,861 
Abstain 24,589,711 
Non-Votes 346,482,920 

9.    Shareholder Proposal - Report on Public Health Costs of Protecting Vaccine Technology:
For 156,919,718 
Against 1,650,063,722 
Abstain 42,054,151 
Non-Votes 346,482,920 

10.    Shareholder Proposal - Discontinue Global Sales of Baby Powder Containing Talc:
For 279,116,458 
Against 1,506,309,151 
Abstain 63,611,982 
Non-Votes 346,482,920 
11. Shareholder Proposal - Request for Charitable Donations Disclosure:
For 74,744,360 
Against 1,762,811,483 
Abstain 11,481,748 
Non-Votes 346,482,920 

12. Shareholder Proposal - Third Party Review and Report on Lobbying Activities Alignment with Position on Universal Health Coverage:
For 794,680,143 
Against 1,042,341,388 
Abstain 12,016,060 
Non-Votes 346,482,920 

13. Shareholder Proposal - Adopt Policy to Include Legal and Compliance Costs in Incentive Compensation Metrics:
For 877,012,827 
Against 961,185,621 
Abstain 10,839,143 
Non-Votes 346,482,920 

14. Shareholder Proposal - CEO Compensation to Weigh Workforce Pay and Ownership:
For 196,312,525 
Against 1,617,183,502 
Abstain 35,541,564 
Non-Votes 346,482,920 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
  Johnson & Johnson  
Date:  April 29, 2022 By: /s/ Matthew Orlando  
    Matthew Orlando

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more Johnson and Johnson Charts.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more Johnson and Johnson Charts.